Thermo Fisher Scientific Inc

• Stryker faced downward pressure and volatility amid pre earnings caution and sector rebalancing. • The company invested four hundred million dollars in CMR Surgical for robotics expansion. • Stryker reported annual revenue of $25.12B and net profit of $3.25B.

• Abbott lowered its full-year comparable sales growth forecast to approximately 6 percent. • The company announced plans to spin off its nutrition segment by late 2027. • Third-quarter revenue and adjusted earnings per share met general market consensus expectations.

• Danaher reported strong third-quarter earnings and upgraded its full-year guidance. • Core revenue growth accelerated alongside notable operating margin expansion and cash flow. • The stock exhibits a MACD buy signal and neutral RSI conditions.

• UnitedHealth reported strong third-quarter results and raised its full-year profit forecast. • Major brokerages upgraded price targets following positive Medicare Advantage and Medicaid margin trends. • The stock exhibits bullish technical indicators alongside an annual revenue of $447.93B.

• Analysts raised price targets citing stabilizing bioprocessing and life sciences sector recovery. • Danaher partnered with NVIDIA to integrate AI into laboratory equipment platforms. • Danaher reported annual revenue of $24.57B and net profit of $3.61B.

• Thermo Fisher showed high volatility ahead of its quarterly earnings release. • Annual revenue reached $44.56B with net profit totaling $6.70B. • Analysts maintain Buy ratings with an average price target of $683.61.